Topp, M S
Stelljes, M
Zugmaier, G
Barnette, P
Heffner, L T Jr
Trippett, T
Duell, J
Bargou, R C
Holland, C
Benjamin, J E
Klinger, M
Litzow, M R
Article History
First Online: 9 October 2017
Competing interests
: MST: Research support and/or consulting fees from Amgen, Roche, Regeneron, Affimed, Jazz, Gilead and Pfizer. MS: Research grants from Pfizer. Consulting fees from Amgen, Pfizer and Jazz. Speakers bureau for Amgen and Pfizer. GZ, JEB: Employees and stockholders of Amgen. LTH: Research support from Amgen. Honoraria from Amgen and Pfizer. RCB: Consulting fees from Amgen, Novartis, AstraZeneca, Pfizer, Genmab, GEMoaB GmbH and Cellex. Patents/royalties for blinatumomab. CH: Employee and stockholder of Amgen. Stockholder of MacroGenics. MK: Employee and stockholder of Amgen. Inventor remuneration due to blinatumomab-related patent. MRL: Research grants from Amgen. The remaining authors declare no conflict of interest.